Women with thrombophilia: Assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue SUPPL. 1, 1998, Pages 33-39

  Waselenko, Jamie K ^a   Nage, Mary Catherine ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Hormone replacement therapy; Oral contraceptives; Thrombophilia; Thrombosis

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

DISEASE ASSOCIATION; HORMONE SUBSTITUTION; HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOPHILIA; THROMBOSIS; TREATMENT PLANNING;

CONTRACEPTIVES, ORAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 0031762076     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88: 3698-3703
2. Hillarp A, Zoller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemostas 1997;78:990-992
3. Rosendaal F. Risk factors for venous thrombosis: Prevalence, risk, and interaction. Semin Hematol I997;34:171-187
4. Gumming AM, Keeney S, Salden A, et al. The prothrombin gene G20210A variant: Prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997;98:353-355
5. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993:342:1503-1506
6. Hellgren M, Svensson PJ, Dahlba'ck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;1973:2!0-213
7. Price DT, Ridker PM. Factor V Leiden mutation and the risk for thromboembolic disease: A clinical perspective. Ann Intern Med 1997;127:895-903
8. Fotherby K, Caldwell ADS. New progestogens in oral contraception. Contraception 1994;49:l-32
9. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, Biiller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-1596
10. Farmer RDT, Lawrcnson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-88
11. Jick H, Jick SS, Gurewich V, Myers M\V, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-1593
12. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Br Med J 1996; 312:83-88
13. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995:346:15821588
14. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1575-1582
15. Suissa S, Biais, Spitzer WO, et al. First time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997:56:141-46
16. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of Factor V Leiden mutation. Lancet 1994;344:1453-1457
17. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for Factor V Leiden. Br J Haematol 1996;93:487-490
18. Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemostas 1998; 79:28-31
19. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischémie stroke and combined oral contraceptives: Results of an international, muticentre, casecontrol study. Lancet 1996:348:498-505
20. Heinemann LAJ, Lewis MA, Spitzer WO, et al. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Contraception 1998;57:29-37
21. Middeldorp S, Henkens CMA, Koopman MMW, et al. The incidence of venous thromboembolism in family members of patients with Factor V Leiden limitation and venous thrombosis. Ann Intern Med 1998:128:15-20
22. Heimerhorst FM, Bloemenkamp KWM, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: Risk of venous thromboembolism. Thromb Haemostas 1997:78: 327-333
23. Schwanz J, Freeman R, Frishman W. Clinical pharmacology of estrogens: Cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol 1995;35:314-329
24. Durand JL, Bresslev R. Clinical pharmacology of the steroidal oral contraceptives. Adv Intern Med 1979;24:97-126
25. Thacker HL. Current issues in menopausal hormone replacement therapy. Cleveland Clin J Med 1996:63:344-353
26. Grodstein F, Stampfer MJ, Goldhaber SZ. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996:348:983-987
27. Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996;348: 981-983
28. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996:348:977-980
29. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. Br MedJ 1997:314:796-800
30. Arden NK, Lloyd ME, Spector TD, Hughes GRV. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994;3:11-13
31. Quinn DA, Thompson T, Terrin M, et al. A prospective investigation of pulmonary embolism in women and men. JAMA 1992;268:1689-1696
32. Sellers TA, Mink PJ, Cerhan JR et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973-980
33. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059
34. Tang M-X, Jacobs D, Stern Y, et al. Effective of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996:348:429-432
35. The Writing Group for the PEPI Trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Postmenopausal Estrogen/ Progestin Intervention (PEPI) Trial. JAMA 1995;273:199208
36. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996:335:453-461
37. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336: 1769-1775
38. Tonnes Pedersen A, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet 1997:350:1277-1283
39. Sidney S, Petitti DB, Quesenberry CP. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997;127:501-508
40. Heckbert SR, Weiss NS, Koepsell TD, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 1997:157:1330-1336 :
41. Rizzoli R, Bonjour J-P. Hormones and bones. Lancet 1997; 349:5120-123
42. Delmas PD, Bjamason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endomctrium in postmenopausal women. N Engl J Med 1997:337:1641-1647
43. EVISTA: Prescribing and Patient Information. Important information for patients using EVISTA for the prevention of osteoporosis after menopause. Available at: hllp://\r\v\r.e\'ista.com/ pi.htmlffpatient. Accessed March 1, 1998
44. McNagny SE, Kass Wenger N, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med I997;I27: 1093-1096
45. McNagny SE, Jacobson TA. Use of postmenopausal hormone replacement therapy by African American women. The importance of physician discussion. Arch Intern Med 1997;157: 1337-1342
46. Ghali WA, Freund KM, Boss RD, Ryan CA, Moskowitz MA. Menopausal hormone therapy: Physician awareness of patient attitudes. Am J Med 1997:103:3-10
47. Rozenberg S, Kroll M, Vandromme J. Decision factors influencing hormone replacement therapy. Br J Obstet Gynaecol 1996; 103:92-98
48. Douketis JD, Ginsberg JS, Holbrook A, et al. A re-evaluation of the risk for venous thromboembolism with use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997:157:1522-1530